Treatment of HIV-associated nephropathy

Jonathan A. Winston, Godfrey C. Burns, Paul E. Klotman

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


HIV-Associated Nephropathy (HIVAN) is the most common cause of chronic renal disease in HIV-1 infected patients. The disease occurs predominantly in blacks between the ages of 20 and 64. In this population it is currently the third leading cause of end-stage renal disease. The majority of patients with HIVAN have an AIDS-defining condition when the kidney disease is diagnosed. Without treatment they progress to end-stage renal disease within weeks to months. Patients with HIVAN should be treated with highly active antiretroviral therapy (HAART). Treatment should prolong survival and may improve or stabilize kidney function. Steroids have short-term benefits but long-term benefits have not been shown. Converting enzyme inhibitors (CEI) seem to stabilize kidney function and appear to be most effective when administered early in the course of HIVAN. A randomized controlled trial comparing HAART therapy to HAART and CEI should be performed. (C) 2000 by W.B. Saunders Company.

Original languageEnglish
Pages (from-to)293-298
Number of pages6
JournalSeminars in Nephrology
Issue number3
StatePublished - 2000


Dive into the research topics of 'Treatment of HIV-associated nephropathy'. Together they form a unique fingerprint.

Cite this